Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004004 · ClinicalTrials.gov registry record · Phase 1

Procarbazine in Treating Patients With Recurrent Brain Tumor

A Phase 1 study, sponsored by New Approaches to Brain Tumor Therapy Consortium.

Completed
Registry status
Phase 1
Development phase

NCT00004004 is a Phase 1 study that has completed, run by New Approaches to Brain Tumor Therapy Consortium.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004004, a Phase 1 study, has completed, sponsored by New Approaches to Brain Tumor Therapy Consortium.

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of procarbazine in treating patients who have progressive or recurrent astrocytoma, oligodendroglioma, or glioblastoma multiforme following treatment with radiation therapy.

Interventions

  • DRUG procarbazine hydrochloride

Trial Details

FieldValue
Start Date 1999-07
Est. Completion 2003-08
Phase Phase 1

What the Registry Record Tells You About NCT00004004

The ClinicalTrials.gov registry entry for NCT00004004 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is New Approaches to Brain Tumor Therapy Consortium, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which procarbazine hydrochloride is the first listed.

NCT00004004 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00004004 about?

NCT00004004 is a clinical study titled "Procarbazine in Treating Patients With Recurrent Brain Tumor". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of procarbazine in treating patients who have progressive or recurrent astrocytoma, oligodendroglioma, or glioblastoma multifo...

What is the current status of trial NCT00004004?

This trial is currently completed. It is a Phase 1 study. The study started on 1999-07. Estimated completion is 2003-08.

What interventions are being tested in trial NCT00004004?

The interventions under investigation include: procarbazine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00004004?

This trial is sponsored by New Approaches to Brain Tumor Therapy Consortium, which has 10 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.